Bivalent IAP Antagonists for Ovarian Cancer and Hepatitis B
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancers such as ovarian cancer and chronic hepatitis B infections are limited in effectively antagonizing inhibitor of apoptosis proteins (IAPs), which are crucial for programmed cell death and viral elimination.
Innovation Solution
Development of compounds according to Formula I, which are stereoisomers or pharmaceutically acceptable salts, that antagonize host cell IAPs, allowing for the formulation of pharmaceutical compositions to treat IAP-mediated disorders and conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for cancers and chronic hepatitis B infections, then treatment options are available, but the effectiveness in antagonizing inhibitor of apoptosis proteins (IAPs) is limited
Solution Approach 1:
The patent modifies the chemical structure by changing parameters such as substituting different R groups (R1-R6) with various alkyl, cycloalkyl, aryl, heterocyclyl groups and adjusting linker structures to create compounds with enhanced IAP antagonistic activity while maintaining pharmacological properties
Solution Approach 2:
The patent creates composite molecular structures combining multiple functional groups and moieties into a single bivalent compound framework that simultaneously targets IAP proteins, integrating hydrophobic regions, hydrogen bonding capabilities, and spatial positioning elements to achieve superior antagonistic effect
2Reliability
If compounds according to Formula I are developed to antagonize IAPs, then therapeutic efficacy is improved, but molecular complexity increases
Solution Approach 1:
The bivalent compound is segmented into distinct functional modules including a core structure with R1-R6 substituents, linker regions, and terminal functional groups, allowing systematic optimization of each segment's contribution to IAP binding while managing overall molecular complexity
Solution Approach 2:
The patent designs a universal bivalent compound scaffold that can perform multiple functions: binding to IAP proteins, maintaining appropriate spatial orientation, providing hydrophobic and hydrophilic interactions, and allowing for metabolic stability, thereby reducing the need for separate molecular features for each function
Data Source
AI summary
The present technology is directed to compounds, compositions, and methods related to treatment of cancers and viral infections mediated by IAPs, e.g., compounds of Formula I (including Formulas IA, IB, IC, ID, IE, IF, and IG), a stereoisomer thereof, or a pharmaceutically acceptable salt of the compound or the stereoisomer of the compound. In particular, the present compounds and compositions may be used to treat IAP-mediated ovarian cancer and hepatitis B infection.